NASDAQ · Financial Statements

Eikon Therapeutics, Inc. (EIKN) Revenue, Earnings & Financial Statements

$5.15 NASDAQ: EIKN Market Cap $278.81M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Eikon Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $324.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Income Statement — 1 Years (USD millions)

Metric2025
Revenue$0
Operating Expenses$339.0M
Operating Profit−$339.0M
Other Income$15.0M
Interest$1.0M
Depreciation$24.0M
Profit Before Tax−$324.0M
Tax rate (%)0.0%
Net Profit−$324.0M
EPS−$6.16

Quarterly Results — Last 5 Quarters (USD millions)

MetricSep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0
Operating Expenses$75.0M$83.0M$87.0M$93.0M$91.0M
Operating Profit−$75.0M−$83.0M−$87.0M−$93.0M−$91.0M
Interest$0$0$0$0$4.0M
Profit Before Tax−$71.0M−$80.0M−$83.0M−$88.0M−$86.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%
Net Profit−$71.0M−$80.0M−$83.0M−$88.0M−$86.0M
EPS$0.00−$1.47−$1.53−$1.63−$1.59

Balance Sheet — 1 Years (USD millions)

Metric2025
Total Assets$595.0M
Current Assets$349.0M
Cash$105.0M
Inventory$0
Receivables$0
Fixed Assets$234.0M
Capital Work in Progress$0
Investments$231.0M
Other Assets$0
Total Liabilities$1.5B
Current Liabilities$55.0M
Borrowings$257.0M
Other Liabilities$1.2B
Equity$0
Reserves−$879.0M

Cash Flow Statement — 1 Years (USD millions)

Metric2025
Operating Cash Flow−$189.0M
Investing Cash Flow−$228.0M
Financing Cash Flow$0
Net Cash Flow−$18.0M
Free Cash Flow−$235.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-1.58
FCF Yield-71.78%
Quick Ratio9.89
Interest Coverage-339.00
Return 1Y—
Return 3Y—
Return 5Y—

Eikon Therapeutics, Inc. (EIKN) financials — frequently asked questions

What is Eikon Therapeutics, Inc.'s annual revenue?

Eikon Therapeutics, Inc. (EIKN) reported annual revenue of $0 in its most recent fiscal year.

What is Eikon Therapeutics, Inc.'s net profit?

Eikon Therapeutics, Inc. (EIKN) reported a net loss of $324.0M in its most recent fiscal year.

What is EIKN EV/EBITDA?

Eikon Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.58. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
EIKN Overview EIKN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.